SUPER HI (09658) announces its interim financial results, with a net profit attributable to shareholders of 28.352 million USD.
(09658) announced its six-month performance ending on June 30, 2025, with a revenue of $397 million.
SUPER HI (09658) announced its six-month performance ending on June 30, 2025, with revenue of 397 million US dollars, a year-on-year growth of 7.0%; the company's attributable profit to owners was 28.352 million US dollars, compared to a loss of 4.583 million US dollars in the same period last year; basic earnings per share were 0.05 US dollars.
In the first half of 2025, HAIDILAO restaurants had an average table turnover rate of 3.9 times per day, an increase of 0.1 times compared to the same period last year; the same-store average table turnover rate remained the same as in 2024, at 3.9 times per day; same-store revenue increased by 3.0%. The operating profit margin at the restaurant level was 6.4%, a decrease of 2.3 percentage points compared to the previous year, which was in line with the company's expected profit-sharing policy, but it also reflected shortcomings in the company's fine management in the dynamic operating process.
During the reporting period, the company continued to optimize its global restaurant network through a "bottom-up" approach. In the first half of 2025, the company opened 8 new HAIDILAO restaurants, while continuing to implement the "Woodpecker Plan" in Southeast Asia and East Asia, closing 4 underperforming stores. As of June 30, 2025, the company operated a total of 126 HAIDILAO restaurants in international markets, including 74 in Southeast Asia, 20 in East Asia, 20 in North America, and 12 in other regions.
Related Articles

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.
.png)
Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
.png)
RECOMMEND

Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025

U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025

Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025